AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01428362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00003800 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: immunohistochemistry staining method
Study NCT00003800 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: laboratory biomarker analysis
Study NCT00003800 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: radionuclide imaging
Study NCT03004443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab will be administered intravenously (IV) as 5 mg/kg body weight over a 2 to 2.5 hour period.
Study NCT02090114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
Study NCT02090114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
Study NCT03742336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Single oral 200 mg dose of PF-04965842
Study NCT03742336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Single 75 mg dose of dabigatran
Study NCT03222479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress guide
Description: smartphone-based application that can evaluate stress level and teach how to manage their stress
Study NCT03604471 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: Blood sampling for atorvastatin quantification and pharmacogenetic analysis.
Study NCT04532463 — intervention group
Intervention type: DRUG
Intervention: Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week
Description: To study the clinical effectiveness and safety of amphotericin B with flucytosine-fluconazole therapy for cryptococcal meningitis in patients with HIV infection.
Study NCT03004443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution will be administered intravenously over a 2 to 2.5 hour period.
Study NCT04126174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual LRI
Description: Manual LRI
Study NCT03366831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thirty Million Words Initiative Newborn Intervention
Description: The Thirty Million Words Initiative Newborn Intervention (TMW-Newborn) is a public health effort aimed at increasing awareness about the importance of a child's early language environment in his or her first years of life. This one-time educational intervention will be impacting maternal awareness and knowledge about the importance of children's early language environment, between ages 0 and 3.
Study NCT04007731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DrRip - high protein, high fibre and creatine load
Description: A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
Study NCT04007731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Voltage energy bar
Description: A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
Study NCT02637336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture in point 6 of the pericardium channel (neiguan) bilaterally
Study NCT03657485 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: containing Bifidobacterium breve PB04, Lactobacillus rhamnosus KL53A
Description: we supplemented the probiotic orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
Study NCT03908294 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lab tests, non-invasive fibrosis (Fibroscan/ARFI)
Description: Patient characteristics, lab values reflecting glucose metabolism and non-invasive fibrosis tests are documented at baseline, during therapy and up to one year after end of treatment.
Study NCT02637336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: aerobic exercise of moderate intensity
Study NCT02637336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: inhalation of eucalyptus essential oil
Study NCT03368703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct-current-stimulation
Description: 2mA / 20min Anodal and Sham tDCS over dominant M1. Anodal tDCS consists of 30s of ramp up followed by 20min of stimulation and 30s of ramp down.
Study NCT03368703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal transcranial direct-current-stimulation
Description: 2mA / 20min Anodal and Sham tDCS over dominant M1. Anodal tDCS consists of 30s of ramp up followed by 20min of stimulation and 30s of ramp down.
Study NCT03546257 — intervention group
Intervention type: DEVICE
Intervention: magnifying endoscopy with narrow band imaging (ME-NBI)
Description: A system consisting of a magnifying endoscope combined with narrow-band imaging (NBI), with the spectral band width narrowed by optical filters, was developed to enhance visualization of mucosal surface structure and vascular architecture. There were some reports that the magnifying endoscopy with narrow band imaging (ME-NBI) is superior to predict the histologic differentiation, depth of invasion and lesion margin than WLE.
Study NCT03368703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial direct-current-stimulation
Description: Sham tDCS consists of only 30s of ramp up followed by 30s of ramp down and no further stimulation.~Participants therefore have the same feeling for both modalities : slight itching due to the induced current at the beginning of the protocol (during around 30s) allowing no differentiation by the participant between the anodal or sham sessions.
Study NCT03368703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham transcranial direct-current-stimulation
Description: Sham tDCS consists of only 30s of ramp up followed by 30s of ramp down and no further stimulation.~Participants therefore have the same feeling for both modalities : slight itching due to the induced current at the beginning of the protocol (during around 30s) allowing no differentiation by the participant between the anodal or sham sessions.
Study NCT00116428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVISTAR® THERMOCOOL® Catheter
Description: The Biosense Webster NAVISTAR® THERMOCOOL® Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
Study NCT00116428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug
Description: Subjects randomized to the antiarrhythmic drug (control) arm will be prescribed to a not previously administered class I or class III antiarrhythmic drug that is currently approved in the U.S. for treating atrial fibrillation.
Study NCT01438073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kisspeptin 112-121
Description: 24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)
Study NCT01438073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: Single intravenous dose of GnRH (2.5-250 ng/kg)
Study NCT03697057 — intervention group
Intervention type: PROCEDURE
Intervention: General anaesthesia
Description: Standard general anaesthesia for gynecologic surgery in patient group
Study NCT01370668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional remediation
Description: The functional remediation program is composed of 21 weekly sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.~The program will be performed in an 12- to 15-patient group conducted by 2 experienced neuropsychologists with previous experience with bipolar patients and specific training on patients' group management.
Study NCT01370668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Group psychoeducation is a tested and manualized intervention consisting of 21 weekly sessions of 90 minutes aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences, and lifestyle regularity.
Study NCT01370668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The patients will not receive any add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
Study NCT04281641 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TCHP
Description: Drug: Trastuzumab 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV Other Name: Herceptin~Drug: Pertuzumab 840 mg as a loading dose, then 420 mg every 3 weeks, IV Other Name: Perjeta~Drug: carboplatin at target area under the plasma concentration-time curve (AUC) 6~Drug: docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w).~All study drugs were administered intravenously.~Procedure: 18-FDG-PET and 68 Ga-Affibody HER-2 Imaging PET will be performed at baseline, on day 15 and before surgery~Genomic alterations (mutations/somatic rearrangements) are detected at baseline, on day 15 and before surgery.
Study NCT02595359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin intracameral
Study NCT02713204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN910-3
Study NCT02713204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI)
Study NCT04583566 — intervention group
Intervention type: GENETIC
Intervention: COVID-19 Diagnostic and Assessment Tests
Description: Complete Blood Count (CBC), Differential leukocytes, D-dimer, C-Reactive Protein, Polymerase Chain Reaction (PCR) Test, Ferritin level, Cytokines Profile, Transcriptome Analysis, miRNA Analysis.
Study NCT02395783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 10 µg
Description: Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
Study NCT02395783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 20 µg
Description: Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
Study NCT02395783 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
Study NCT03501706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequenced Recall of Digits--Auditory
Description: Auditory digit sequence AT memory component.
Study NCT03501706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequenced Reverse Recall of Digits--Auditory
Description: Reversed auditory digit sequence AT memory component.
Study NCT03501706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequenced Recall of Words--Visual
Description: Visual word sequence AT memory component
Study NCT02864719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Conservation+Problem Solving Therapy
Description: The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
Study NCT01974154 — intervention group
Intervention type: OTHER
Intervention: Cohort I
Description: We will evaluate serum and lung ELF obtained by bronchoalveolar lavage, under previous protocols, from 159 individuals at baseline and at 0, 3, 6 and 12 months.
Study NCT03501706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verbal Memory--Visual
Description: word recognition AT memory component
Study NCT01974154 — intervention group
Intervention type: OTHER
Intervention: Cohort II
Description: Quantify the cilia length on prepared slides from 67 cohort II samples of airway epithelium from biological samples were already obtained from subjects who were consented to participate in prior WCMC IRB approved protocols.
Study NCT03896685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline 100 MG
Description: Bedaquiline: 400 mg QD x 2 weeks, followed by 200 mg 3x/week
Study NCT04964830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic treatment with functional appliance (MAD)
Description: Expansion plate and z-activator (MAD)
Study NCT04598165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive two-way SMS dialogue
Description: We will utilize Mobile WACh, a human-computer hybrid system that enables seamless two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated theoretically grounded SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day for the remaining four weeks. Women who experience pregnancy or infant loss will be enrolled into an infant loss track where they will receive messages of support.
Study NCT03896685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid 50 MG Oral Tablet
Description: Delamanid: 100 mg BID
Study NCT03896685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine 100 MG Oral Capsule
Description: Clofazimine: 100 mg QD
Study NCT03896685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid 600Mg Tab
Description: Linezolid: 600 mg QD up to Week 16, followed by 300 mg QD or 600 mg 3x/week according to a secondary randomization
Study NCT03896685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control arm MDR-TB regimen, designed according to latest WHO guidelines
Description: Control arm MDR-TB regimen, designed according to latest WHO guidelines (might include bedaquiline, delamanid, linezolid, clofazimine, or all of these drugs).
Study NCT03029273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and Fludarabine
Description: Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with cyclophosphamide (250-500mg/m2/day) plus fludarabine (25mg/m2/day) for 3 days.
Study NCT03029273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-NY-ESO-1 TCR transduced T cells
Description: A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (500,000 IU/day) will be administered for 14 days concomitantly to each subject.
Study NCT00187031 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topotecan, Filgrastim (G-CSF), Pegfilgrastim
Description: See detailed description section for additional details.
Study NCT02101203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02101203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mgTestosterone + 10 mg Buspirone
Description: A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, on demand) throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days).
Study NCT04149873 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MIE
Description: MIE
Study NCT04149873 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIE
Description: MIE
Study NCT01962831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Study NCT01962831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single balloon foley catheter
Study NCT02001181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib ointment 20mg/g
Description: Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
Study NCT02001181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment (Vehicle)
Description: Placebo ointment (vehicle) twice daily (BID) for 4 weeks
Study NCT04483323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: The patient will be placed in the lateral position. Following skin disinfection, counting down from the C7 spinous process and using ultrasound guidance, the level of T2 transverse process will be identified. A 2-5 MH2 curved array transducer (sono site Edge, Bothell, Will behington) will be positioned transversely to visualize the lateral tip of T2 transverse Process. A longitudinal parasagittal orientation will be obtained over the transverse process using a 22 - gauge 8 cm block needle (visioplex, Vygon , France) will be inserted in plane to US beam in a caudal to cranial direction to place the needle tip between the posterior fascia of the erector spinae muscle and the T2 transverse process.~Position of the needle tip in the ESP deep to the erector spinae muscle will be confirmed using hydrodissection with 0.5 - 1 ml of normal saline and visualization of the linear fluid spread deep to the erector spinae muscle following which 20 ml of 0.25% bupivacaine will be injected.
Study NCT04483323 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular Injection
Description: Intraarticular injection of local anesthetic through the surgical port
Study NCT02534220 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Toothbrush
Description: Gum Delicate Post-Surgical Toothbrush, Oral-B, Procter \& Gamble, Cincinnati, OH
Study NCT02534220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oscillating-rotating toothbrush
Description: Triumph 5000, Oral-B, Procter \& Gamble, Cincinnati, OH
Study NCT01931332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block with levobupivicaine
Description: A single injection femoral nerve block (FNB) performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hz with pulse width 0.1ms. Once a quadriceps muscle twitch is identified at a stimulated current between 0.2 and 0.5mA, 20mls of 0.375% levobupivacaine (75mg) is injected in fractionated amounts after negative aspiration
Study NCT01931332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal injection of diamorphine
Description: 500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
Study NCT04461288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social media-based education, counseling, and support
Description: This six-month intervention is culturally-tailored to sexual and gender minority cigarette smokers. The intervention is group-based and includes daily posts and weekly live sessions during the initial three months. Posts and group sessions focus on tobacco use education, developing a quit plan, as well as managing stress, negative thinking, social support, exercise, as techniques to support cessation.
Study NCT04461288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapies (NRT)
Description: Participants will have access to up to six months of nicotine patch therapy. Participants will start on either 21, 14, or 7 mg patches based on manufacturers recommendations based on smoking behaviors.~In addition to nicotine patch, participants will have access to a choice of 2 mg. nicotine lozenges or nicotine gum as an adjunct to patch treatment. Participants will be encouraged to use up to 5 pieces daily to address situational urges and cravings for a cigarette.
Study NCT04461288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapies (NRT)
Description: Participants will have access to up to six months of nicotine patch therapy. Participants will start on either 21, 14, or 7 mg patches based on manufacturers recommendations based on smoking behaviors.~In addition to nicotine patch, participants will have access to a choice of 2 mg. nicotine lozenges or nicotine gum as an adjunct to patch treatment. Participants will be encouraged to use up to 5 pieces daily to address situational urges and cravings for a cigarette.
Study NCT04461288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamification
Description: Gaming elements designed to encourage participation in the program and behavior change.